MX2019007012A - Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile. - Google Patents

Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile.

Info

Publication number
MX2019007012A
MX2019007012A MX2019007012A MX2019007012A MX2019007012A MX 2019007012 A MX2019007012 A MX 2019007012A MX 2019007012 A MX2019007012 A MX 2019007012A MX 2019007012 A MX2019007012 A MX 2019007012A MX 2019007012 A MX2019007012 A MX 2019007012A
Authority
MX
Mexico
Prior art keywords
tcdb
treatment
response
clostridium difficile
genetic markers
Prior art date
Application number
MX2019007012A
Other languages
English (en)
Inventor
V Mehrotra Devan
M Shaw Peter
L Blanchard Rebecca
Shen Judong
Mogg Robin
Beth Dorr Mary
Li Junhua
Xu Xun
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/109900 external-priority patent/WO2018107388A1/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019007012A publication Critical patent/MX2019007012A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona marcadores genéticos en el cromosoma humano 6 que están asociados con una respuesta beneficiosa a un tratamiento que se dirige a la toxina B (TcdB) de Clostridium difficile (C. difficile), por ejemplo, un anticuerpo TcdB. Estos marcadores de respuesta al tratamiento con TcdB son útiles, entre otros, para identificar a los pacientes que tienen más probabilidades de beneficiarse del tratamiento con un tratamiento que se dirige a TcdB en métodos para tratar a pacientes que tienen una enfermedad susceptible al tratamiento con un anticuerpo TcdB, y en métodos para seleccionar la terapia más adecuada para estos pacientes. La invención también proporciona anticuerpos, productos farmacéuticos y kits útiles con los marcadores de respuesta al tratamiento con TcdB de la invención.
MX2019007012A 2016-12-14 2017-12-07 Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile. MX2019007012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2016/109900 WO2018107388A1 (en) 2016-12-14 2016-12-14 Human genetic markers associated with response to treatments that target clostridium difficile toxin b
US201762508066P 2017-05-18 2017-05-18
PCT/US2017/064985 WO2018111662A1 (en) 2016-12-14 2017-12-07 Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Publications (1)

Publication Number Publication Date
MX2019007012A true MX2019007012A (es) 2019-11-28

Family

ID=62559092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007012A MX2019007012A (es) 2016-12-14 2017-12-07 Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile.

Country Status (9)

Country Link
US (1) US12071666B2 (es)
EP (1) EP3555303B1 (es)
JP (2) JP2020502179A (es)
CN (1) CN110088300A (es)
AU (1) AU2017375590A1 (es)
BR (1) BR112019012203A2 (es)
MX (1) MX2019007012A (es)
RU (1) RU2761249C2 (es)
WO (1) WO2018111662A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2761249C2 (ru) * 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile
CN112481395B (zh) * 2019-09-12 2024-10-18 深圳华大生命科学研究院 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
IE66572B1 (en) 1989-02-13 1996-01-24 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
CA2182517C (en) 1994-02-07 2001-08-21 Theo Nikiforov Ligase/polymerase-mediated primer extension of single nucleotide polymorphisms and its use in genetic analysis
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
IL124967A (en) 1995-12-18 2000-07-26 Univ Washington Method for nucleic acid analysis using fluorescence resonance energy transfer
WO1998020019A1 (en) 1996-11-06 1998-05-14 Sequenom, Inc. Compositions and methods for immobilizing nucleic acids to solid supports
DE19782096T1 (de) 1996-11-06 2000-03-23 Sequenom Inc Immobiliserung von Nucleinsäuren in hoher Dichte
EP2121985A4 (en) * 2007-03-27 2011-01-05 Univ Duke GENETIC VARIANTS ASSOCIATED WITH RESTRICTION OF HIV DISEASE
US20100035265A1 (en) * 2008-07-18 2010-02-11 Aris Floratos Biomarkers for Drug-Induced Liver Injury
WO2010050829A1 (en) * 2008-10-31 2010-05-06 Vialactia Biosciences (Nz) Limited Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype
MY152062A (en) 2009-02-24 2014-08-15 Merck Sharp & Dohme Indole derivatives as crth2 receptor antagonists
CN102770140B (zh) * 2009-08-21 2017-06-23 诺瓦蒂斯公司 治疗癌症的方法
SI2758432T1 (sl) * 2011-09-16 2019-07-31 Ucb Biopharma Sprl Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
EP2771033A4 (en) * 2011-10-28 2016-02-17 Integritybio Inc PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
WO2014110493A1 (en) * 2013-01-11 2014-07-17 Baylor College Of Medicine Biomarkers of recurrent clostridium difficile infection
AU2014273850A1 (en) * 2013-05-29 2015-12-17 Immunexpress Pty Ltd Microbial markers and uses therefor
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
CN103665141B (zh) * 2013-12-31 2015-09-16 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
RU2761249C2 (ru) * 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile
WO2018107388A1 (en) * 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Also Published As

Publication number Publication date
US20200017909A1 (en) 2020-01-16
RU2019122099A3 (es) 2021-04-16
RU2761249C2 (ru) 2021-12-06
JP2020502179A (ja) 2020-01-23
EP3555303A4 (en) 2020-06-24
EP3555303B1 (en) 2022-12-21
JP2023055222A (ja) 2023-04-17
RU2019122099A (ru) 2021-01-15
BR112019012203A2 (pt) 2019-11-12
CN110088300A (zh) 2019-08-02
WO2018111662A1 (en) 2018-06-21
US12071666B2 (en) 2024-08-27
EP3555303A1 (en) 2019-10-23
AU2017375590A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
WO2016070051A3 (en) Combination therapy for treatment of disease
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2019011858A (es) Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos.
EP4085919A3 (en) Compositions and methods to treat cancer
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2017015962A (es) Uso de exosomas para el tratamiento de enfermedades.
EA201892803A1 (ru) Противоопухолевая терапия
MX2018010508A (es) Preparaciones mejoradas de celulas progenitoras hepaticas adultas.
WO2017040666A3 (en) Combination therapy for treatment of disease
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR112022003956A2 (pt) Anticorpos anti-cd73
WO2017192662A3 (en) Methods for identifying treatment targets based on multiomics data
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
EP3541943A4 (en) MICRO-ORGANISM FOR ADMINISTERING A MEDICINAL PRODUCT FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE, WHICH EXPRESSES AND SECRETS P8 PROTEIN, AND PHARMACEUTICAL COMPOSITION CONSISTING OF THIS MICRO-ORGANISM FOR THE PREVENTION OR TREATMENT OF A GASTROINTESTINAL DISEASE
WO2018212361A8 (en) Method of treating diseases associated with myd88 pathways using crispr-gndm system
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
MX2019007012A (es) Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile.
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
BR112016023011A2 (pt) tratamento de câncer gástrico